ZNF660 and pachyonychia congenita: Hypermethylation of ZNF660 was also significantly associated with decreased OS and CSS after RP in a cohort with long clinical follow‐up time (HRs 5.09 and 7.70, respectively), together suggesting that ZNF660 has the potential to improve risk stratification for patients with PC.